Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma

<p>Summary statistics for nucleosome footprints at YES1 and IGF1R regulatory motifs</p>

Saved in:

Bibliografiske detaljer
Hovedforfatter:	Srivandana Akshintala (16610490) (author)
Andre forfattere:	R. Taylor Sundby (15049851) (author), Donna Bernstein (16610493) (author), John W. Glod (16610496) (author), Rosandra N. Kaplan (16610499) (author), Marielle E. Yohe (15046970) (author), Andrea M. Gross (15086392) (author), Joanne Derdak (16610502) (author), Haiyan Lei (14963261) (author), Alexander Pan (16610505) (author), Eva Dombi (14942359) (author), Isabel Palacio-Yance (16610508) (author), Kailey R. Herrera (16610511) (author), Markku M. Miettinen (16610514) (author), Helen X. Chen (15030084) (author), Seth M. Steinberg (15043179) (author), Lee J. Helman (15049914) (author), Leo Mascarenhas (16610517) (author), Brigitte C. Widemann (15053620) (author), Fariba Navid (16610520) (author), Jack F. Shern (14938001) (author), Christine M. Heske (16610523) (author)
Udgivet:	2025
Fag:	Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Clinical Trial Results Clinical trials in pediatric cancer Phase I clinical trials Drug Targets Cell surface receptor drug targets Protein kinase & phosphatase drug targets Liquid Biopsy Pediatric Cancers Sarcomas Soft-tissue sarcoma
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Lignende værker